Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
London: Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at double ...
The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for Covid-19 vaccines in exchange for a stake that doubles the ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
The Gaithersburg biotech has lifted its going-concern warning after receiving a cash infusion. Novavax Inc. is getting a big cash infusion after signing a multibillion-dollar deal with French ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in ...